-

Voluntis Announces Issuance of European Patent for Drug Dosing Support With Its Theraxium Digital Therapeutic Platform

  • Patented technology used to assist patients in optimizing their drug dosage through intelligent and adaptive algorithms
  • Expansion of Voluntis' existing intellectual property portfolio in the field of digital therapeutics
  • Application in the field of diabetes for insulin titration support

CAMBRIDGE, Mass. & PARIS--(BUSINESS WIRE)--Regulatory News:

Voluntis (Paris:VTX) (Euronext Paris, Ticker: VTX - ISIN: FR0004183960), a leader in digital therapeutics, announced today the issuance of a new patent by the European Patent Office (EPO) for intelligent patient support in drug dosing applied in the field of diabetes for insulin titration support.

Following the prescription of the drug and its companion digital therapeutic, the intelligent and adaptive algorithms developed by Voluntis will automatically recommend to a patient, day by day and according to the evolution of their monitoring data, a progressive increase of the dose to bring the patient into the target range as specified by their physician. Safety mechanisms are also present to decrease the dose if the situation requires it. Once the target range is reached, the dose will then remain stable as long as the patient's follow-up data stays within the target range.

In the field of diabetes, the patent obtained relates to the optimization of insulin titration, based on the evolution of fasting blood glucose levels over several days to recommend to the patient an appropriate dose of basal insulin to be injected, in accordance with their treatment plan. More specifically, this new patent covers the management of the sensitivity of the titration algorithms to changes in the patient's blood glucose levels to optimize the achievement and maintenance of the dose enabling glycemic control.

"Thanks to this patented technology, we are extending the scope of cutting-edge solutions available to our clinical and industrial partners wishing to offer unique treatment experiences to patients worldwide" said Pierre Leurent, Chief Executive Officer. "Successfully dosing drug treatments, particularly in the context of complex therapies, is often a challenge for patients and their healthcare teams, Digital therapeutics now provide innovative solutions thanks to embedded algorithms that provide patients with daily and personalized recommendations, in compliance with the physician's prescription and with performance and safety standards. ".

"We are proud to obtain this new patent, which builds on Voluntis' 15 years of experience in the field of dosage support with digital therapeutics" added Etienne Vial, Chief Technology Officer. "Our Theraxium platform is already being used for drug dosing support in therapeutic areas other than diabetes, particularly in oncology for the dosing of symptomatic treatments. These developments in our platform offer promise to further extend our approach to other therapeutic areas. »

About Voluntis

Voluntis creates digital therapeutics that empower people with chronic conditions to self-manage their treatment every day, thus improving real-world outcomes. Voluntis’ solutions, combining mobile and web apps, use clinical algorithms to deliver personalized recommendations to patients and their care teams. For example, these recommendations are used to adjust treatment dosage, manage side effects or monitor symptoms.

Leveraging its Theraxium technology platform, Voluntis has designed and operates multiple digital therapeutics, especially in oncology and diabetes. Voluntis has long-standing partnerships with leading life science companies. Based in Cambridge, MA, and Paris, France, Voluntis is a founding member of the Digital Therapeutics Alliance.

For more information, please visit: www.voluntis.com

Mnemo : VTX - ISIN : FR0004183960

Disclaimer

This press release contains certain forward-looking statements concerning Voluntis group and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Voluntis considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the 2019 annual financial report and the 2020 half-year financial report published by Voluntis respectively on April 30, 2020 and September 29, 2020 (a copy of which is available on www.voluntis.com) and to the development of economic conditions, financial markets and the markets in which Voluntis operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Voluntis or not currently considered material by Voluntis. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Voluntis to be materially different from such forward-looking statements. Voluntis expressly declines any obligation to update such forward-looking statements.

Contacts

ACTUS
Media relations
Vivien Ferran
vferran@actus.fr
+33 (0)1 53 67 36 34

ACTUS
Investor relations
Jérôme Fabreguettes-Leib
voluntis@actus.fr
+33 (0)1 53 67 36 78

Voluntis
Chief Financial Officer
Guillaume Floch
investisseurs@voluntis.com
+33 (0)1 41 38 39 20

Voluntis

BOURSE:VTX
Details
Headquarters: 58 Avenue de Wagram, France
CEO: Leurent Pierre
Employees: 80
Organization: PRI

Release Versions

Contacts

ACTUS
Media relations
Vivien Ferran
vferran@actus.fr
+33 (0)1 53 67 36 34

ACTUS
Investor relations
Jérôme Fabreguettes-Leib
voluntis@actus.fr
+33 (0)1 53 67 36 78

Voluntis
Chief Financial Officer
Guillaume Floch
investisseurs@voluntis.com
+33 (0)1 41 38 39 20

More News From Voluntis

Voluntis and Eisai to Collaborate on Digital Therapeutics for Oncology Patients

CAMBRIDGE, Mass. & PARIS--(BUSINESS WIRE)--Regulatory News: Voluntis (Euronext Growth Paris, Ticker: ALVTX - ISIN: FR0004183960), a leader in digital therapeutics, today announced a collaboration agreement with Eisai (Headquarters: Tokyo) to design and develop innovative digital therapeutics (DTx) to support patients treated for cancer as well as a strategic investment from Eisai in Voluntis. Collaboration and license agreement further enriching Voluntis’ commercial pipeline By leveraging Volun...

Voluntis: 2020 Annual Results in Line With the Roadmap, Demonstrating the Success of the New Strategy, and Confirmed Confidence in the Plan

CAMBRIDGE, Mass & PARIS--(BUSINESS WIRE)--Regulatory News: Voluntis (Euronext Growth Paris, Ticker: ALVTX - ISIN: FR0004183960), a leader in the field of digital therapeutics, today announced its full year 2020 results as approved by the Board of Directors at its March 29, 2021 meeting. The audit procedures on the accounts have been performed. The certification report will be issued after completion of the procedures required for the publication of the Annual Financial Report. €m   2019 2020 Sa...

Broward Health and Voluntis Launch a New Clinical Evaluation Program on Digital Therapeutics for Metastatic Breast Cancer

DEERFIELD BEACH, Fla. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: Voluntis (Paris:ALVTX) (Euronext Growth Paris, Ticker: ALVTX – ISIN: FR0004183960) a leader in digital therapeutics, announced today a collaboration with Broward Health, a public health system in the U.S. The partnership will focus on conducting a real-world evaluation of Oleena®, a digital application that assists patients in managing their symptoms. As part of the collaboration, Oleena®, a FDA-authorized digital thera...
Back to Newsroom